Mavatar Strengthens Leadership Team with Linda Wakeham as Head of Marketing & Communication

Mavatar, a Swedish pioneer in AI-driven precision medicine, announces the recruitment of Linda Wakeham. Wakeham joins Mavatar from Kronans Apotek, where she served as Head of Communications and PR for the past six years. At Mavatar, she will join the leadership team as Head of Marketing & Communication and will lead the company’s marketing strategy to drive growth and strengthen Mavatar’s position as an innovative force in precision medicine.

“We are excited to welcome Linda Wakeham to Mavatar. Her extensive experience in communication and marketing, combined with her entrepreneurial spirit and international background from fast-growing companies, makes her a perfect fit for our team,” says Johan Juhlin, CEO of Mavatar. Mavatar combines over 20 years of research in precision medicine, advanced machine learning, and artificial intelligence, with the ambition to transform drug development and patient care. Mavatar has developed digital replicas of patients and diseases, known as “medical avatars,” which are unique to each patient. These avatars can predict how patients will respond to real treatments by simulating different treatment options. Mavatar aims to contribute to more precise, personalized, and effective healthcare— from the early stages of drug development to the point of care. “Mavatar’s technology is a game-changer for drug development and personalized healthcare. I’m passionate about innovation and new technologies, and contributing to improved global health has always been one of my driving forces. I look forward to leading the company’s marketing strategy and developing our external communications to accelerate Mavatar’s market penetration and growth,” says Linda Wakeham. Linda Wakeham will assume her role today, December 2nd.

Mavatar’s technology is a game-changer for drug development and personalized healthcare.

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered [insert location], Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.

The Company has partnerships with leading pharmaceutical companies, universities, and hospital systems. These collaborations focus on biobank studies and clinical trials, enabling research scientists to select the best drug candidates, suggest new uses for existing drugs, uncover new therapeutic targets, refine mechanisms of action, and match patients to innovative treatment options through point-of-care decision tools.

Connect with us on LinkedIn.

Original Article link